Role of Lupus Erythematosus Factor and Accessory Serum Factors in Production of Extracellular Nuclear Material
Authors: HARVEY E. GOLDEN
Journal: Annals of Internal Medicine (1967)

Article1 October 1967Role of Lupus Erythematosus Factor and Accessory Serum Factors in Production of Extracellular Nuclear MaterialHARVEY E. GOLDEN, M.D., FREDERIC C. MCDUFFIE, M.D., F.A.C.P.HARVEY E. GOLDEN, M.D.Search for more papers by this author, FREDERIC C. MCDUFFIE, M.D., F.A.C.P.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-67-4-780 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptSince the original description of the lupus erythematosus (LE) cell by Hargraves, Richmond, and Morton (1), it has become clear that this inclusion-containing cell is formed in two stages (2, 3). In the first stage an abnormal gamma G globulin, the LE factor, reacts with a component of the nucleus, apparently the deoxyribonucleic acid-histone complex (4), to form nuclear material that is altered in appearance. This altered nuclear material may then be phagocytized in the second stage to form LE cells, or it may remain extracellular. This altered extracellular nuclear material (ECM) (5) takes several forms, the most commonly recognized...References1. HARGRAVESRICHMONDMORTON MMHR: Presentation of two bone marrow elements: the "tart" cell and the "L.E." cell. Mayo Clin. Proc. 23: 25, 1948. MedlineGoogle Scholar2. RIFKINDGODMAN RAGC: Phase contrast and interferometric microscopy of the L.E. cell phenomenon. J. Exp. Med. 106: 607, 1957. CrossrefMedlineGoogle Scholar3. LACHMANN PJ: A two-stage indirect L.E. cell test. Immunology 4: 142, 1961. MedlineGoogle Scholar4. HOLMANKUNKEL HRHG: Affinity between the lupus erythematosus serum factor and cell nuclei and nucleoprotein. Science 126: 162, 1957. CrossrefMedlineGoogle Scholar5. STEVENSABBEYSHULMAN MBHLE: The clinical significance of extracellular material (ECM) in L.E.-preparations. I. Analysis at the time of the first abnormal test. New Eng. J. Med. 268: 976, 1963. CrossrefMedlineGoogle Scholar6. CARRERAREIDKURNICK AEMVNB: Differences in susceptibility of polymorphonuclear leukocytes from several species to alteration by systemic lupus erythematosus serum: application to a more sensitive L.E. phenomenon test. Blood 9: 1165, 1954. CrossrefMedlineGoogle Scholar7. BERMANAXELRODGOODMANMCCLAUGHRY LARHLRI: So-called "lupus erythematosus inclusion phenomenon" of bone marrow and blood: morphologic and serologic studies. Amer. J. Clin. Path. 20: 403, 1950. CrossrefMedlineGoogle Scholar8. DUBOIS EL: Simplified method for the L.E. cell test: results of a three-year study of seven hundred tests in many disease states. Arch. Intern. Med. (Chicago) 92: 168, 1953. CrossrefGoogle Scholar9. HASERICKBORTZ JRDW: Normal bone marrow inclusion phenomena induced by lupus erythematosus plasma. J. Invest. Derm. 13: 47, 1949. CrossrefMedlineGoogle Scholar10. ARTERBERRYDREXLERDUBOIS JDEEL: Significance of hematoxylin bodies in lupus erythematosus cell preparations. JAMA 187: 389, 1964. CrossrefMedlineGoogle Scholar11. MAYRAWLINS JRGA: A micro method for agar-gel precipitin reactions. J. Clin. Path. 15: 186, 1962. CrossrefMedlineGoogle Scholar12. MACYGLEICH NEGJ: Personal communication to the authors. Google Scholar13. MARDINEYMÜLLER-EBERHARD MRHJ: Mouse β1c-globulin: production of antiserum and characterization in the complement reaction. J. Immun. 94: 877, 1965. MedlineGoogle Scholar14. NELSONJENSENGIGLITAMURA RAJIN: Methods for separation, purification and measurement of nine components of hemolytic complement in guinea pig serum. Immunochemistry 3: 111, 1966. CrossrefMedlineGoogle Scholar15. HASERICKLEWISBORTZ JRLADW: Blood factor in acute disseminated lupus erythematosus. I. Determination of gamma globulin as specific plasma fraction. Amer. J. Med. Sci. 219: 660, 1950. CrossrefMedlineGoogle Scholar16. HOLMANDEICHER HHR: The reaction of lupus erythematosus (L.E.) cell factor with deoxyribonucleoprotein of the cell nucleus. J. Clin. Invest. 38: 2059, 1959. CrossrefMedlineGoogle Scholar17. HOLMANDEICHERKUNKEL HRHRHG: The L.E. cell and the L.E. serum factors. Bull. N. Y. Acad. Med. 35: 409, 1959. MedlineGoogle Scholar18. BARNETTNORTHCONDEMIJACOXVAUGHAN EVAFJJRFJH: Antinuclear factors in systemic lupus erythematosus and rheumatoid arthritis. Ann. Intern. Med. 63: 100, 1965. LinkGoogle Scholar19. TOWNESSTEWARTOSLER ASCRAG: Immunologic studies of systemic lupus erythematosus. I. Quantitative estimations of nucleoprotein-reactive gamma globulin in systemic lupus erythematosus and other diseases. Bull. Hopkins Hosp. 112: 183, 1963. MedlineGoogle Scholar20. TOWNESSTEWARTOSLER ASCRAG: Immunologic studies of systemic lupus erythematosus. II. Variations of nucleoprotein-reactive gamma globulin and hemolytic serum complement levels with disease activity. Ibid., p. 202. Google Scholar21. MANDEMAPOLLAKKARKREZAIAN EVERMJ: Quantitative observations on antinuclear factors in systemic lupus erythematosus. J. Lab. Clin. Med. 58: 337, 1961. MedlineGoogle Scholar22. MORSEMÜLLER-EBERHARDKUNKEL JHHJHG: Antinuclear factors and serum complement in systemic lupus erythematosus. Bull. N. Y. Acad. Med. 38: 641, 1962. MedlineGoogle Scholar23. ROBINEAUX R: Study of L.E. cell formation by phase contrast microcinematography, in Henry Ford Hospital International Symposium: Mechanisms of Hypersensitivity, edited by SHAFFER, J. H., LOGRIPPO, G. A., CHASE, M. W. Little, Brown and Co., Boston, 1959, p. 371. Google Scholar24. ZINKHAMCONLEY WHCL: Some factors influencing the formation of L.E. cells: a method for enhancing L.E. cell production. Bull. Hopkins Hosp. 98: 102, 1956. MedlineGoogle Scholar25. MARMONT A: Nucleolytic phagocytosis (LE cell phenomenon) in systemic lupus erythematosus, rheumatoid arthritis and systemic scleroderma, in International Symposium on Immunopathology, 1st., edited by GRABAR, P., MIESCHER, P. Benno Schwabe & Co., Basel, 1959, p. 479. Google Scholar26. AISENBERG AC: Studies on the mechanism of the lupus erythematosus (L.E.) phenomenon. J. Clin. Invest. 38: 325, 1959. CrossrefMedlineGoogle Scholar27. NAGASHIMAWIEDERMANNHERMANNMIESCHER HGGPA: Influence of 2-mercaptoethanol treatment on opsonizing activity of human and rabbit 7S antibodies. Vox Sang. 10: 333, 1965. CrossrefMedlineGoogle Scholar28. COHNAUSTEN ZAKF: Contribution of serum and cellular factors in host defense reactions. II. Cellular factors in host resistance. New Eng. J. Med. 268: 1056, 1963. CrossrefMedlineGoogle Scholar29. BOYDEN S: The chemotactic effect of mixtures of antibody and antigen on polymorphonuclear leucocytes. J. Exp. Med. 115: 453, 1962. CrossrefMedlineGoogle Scholar30. NELSON RA: The immune-adherence phenomenon: an immunologically specific reaction between microorganisms and erythrocytes leading to enhanced phagocytosis. Science 118: 733, 1953. CrossrefMedlineGoogle Scholar31. NELSON RA: The role of complement in immune phenomena, in The Inflammatory Process, edited by ZWEIFACH, B. W., GRANT, L., MCCLUSKEY, R. T. Academic Press, Inc., Publishers, New York, 1965, p. 819. CrossrefGoogle Scholar32. WARDCOCHRANEMÜLLER-EBERHARD PACGHJ: Further studies on the chemotactic factor of complement and its formation in vivo. Immunology 11: 141, 1966. MedlineGoogle Scholar33. NISHIOKALINSCOTT KWD: Components of guinea pig complement. I. Separation of a serum fraction essential for immune hemolysis and immune adherence. J. Exp. Med. 118: 767, 1963. CrossrefMedlineGoogle Scholar34. JETERMCKEEMASON WSAPRJ: Inhibition of immune phagocytosis of Diplococcus pneumoniae by human neutrophiles with antibody against complement. J. Immun. 86: 386, 1961. MedlineGoogle Scholar35. BOYDENNORTHFAULKNER SVRJSM: Complement and the activity of phagocytes, in Ciba Foundation Symposium: Complement, edited by WOLSTENHOLME, G. E. W., KNIGHT, J. Little, Brown and Co., Boston, 1965, p. 190. CrossrefGoogle Scholar36. VAUGHANBAYLESFAVOUR JHTBCB: The response of serum gamma globulin level and complement titer to adrenocorticotropic hormone (ACTH) therapy in lupus erythematosus disseminatus. J. Lab. Clin. Med. 37: 698, 1951. MedlineGoogle Scholar37. TOWNESSTEWART ASCR: The second and third components of complement in systemic lupus erythematosus (abstract). Arthritis Rheum. 6: 795, 1963. Google Scholar38. MIYASATOPOLLAKBARCELO FVER: Serum beta-1-A (beta-1-C) globulin levels in systemic lupus erythematosus: their relationship to clinical and renal histologic findings. Arthritis Rheum. 9: 308, 1966. CrossrefGoogle Scholar39. FREEDMANMARKOWITZ PAS: Gamma globulin and complement in the diseased kidney. J. Clin. Invest. 41: 328, 1962. CrossrefMedlineGoogle Scholar40. LACHMANNMÜLLER-EBERHARDKUNKELPARONETTO PJHJHGF: The localization of in vivo bound complement in tissue sections. J. Exp. Med. 115: 63, 1962. CrossrefMedlineGoogle Scholar41. LANGETRESERSAGELTYWASSERMAN KGIAE: Routine immunohistology in renal diseases. Ann. Intern. Med. 64: 25, 1966. LinkGoogle Scholar42. FORMIJNEVAN SOEREN PF: Negative L.E.-cell phenomenon in true systemic lupus erythematosus. Lancet 2: 1206, 1958. CrossrefMedlineGoogle Scholar43. CASTANEDOWILLIAMS JPRC: Anticomplementary activity of sera from patients with connective tissue disease and normal subjects. J. Lab. Clin. Med. 69: 217, 1967. MedlineGoogle Scholar44. BIENENSTOCKBLOCH JKJ: Immunoconglutinin in various rheumatic diseases and certain diseases suspected of an autoimmune pathogenesis. Arthritis Rheum. 10: 187, 1967. CrossrefMedlineGoogle Scholar45. LACHMANN PJ: A comparison of some properties of bovine conglutinin with those of rabbit immunoconglutinin. Immunology 5: 687, 1962. MedlineGoogle Scholar46. FINCHDETRE SCKD: Leukotoxicity of pathologic sera and certain drugs (abstract). Clin. Res. 6: 196, 1958. Google Scholar47. NELSONLEBRUN RAJ: The requirement for antibody and complement for in vitro phagocytosis of starch granules. J. Hyg. (Camb.) 54: 8, 1956. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: HARVEY E. GOLDEN, M.D.; FREDERIC C. MCDUFFIE, M.D., F.A.C.P.From the Section of Microbiology, Mayo Clinic and Mayo Foundation, and the Mayo Graduate School of Medicine (University of Minnesota), Rochester, Minn.This investigation was supported in part by training grant AM-5492, National Institutes of Health, Bethesda, Md.This paper was read at the meeting of the American Rheumatism Association, Denver, Colo., June 18, 1966.Requests for reprints should be addressed to Frederic C. McDuffie, M.D., Mayo Clinic, Rochester, Minn. 55901. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byAutoimmune features as determinants of prognosis in steroid-treated chronic active hepatitis of uncertain etiologyLupus erythematodes disseminatusImmunity in Systemic Lupus ErythematosusSystemic Lupus ErythematosusLupus ErythematosusThe Fourth Component of Complement in the Cerebrospinal Fluid in Systemic Lupus Erythematosus"Lupoid" Hepatitis, a Nonentity in the Spectrum of Chronic Active Liver DiseaseII. Development of an indirect LE factor testIII. Presence of LE factor in relatives and spousesDistinctive serum globulin responses to parenteral treatment with 17-β-estradiol in female NZB/NZW miceCurrent status of the LE cell testRole of igg and igm antinuclear antibodies in formation of lupus erythematosus cells and extracellular materialNineteenth rheumatism review. Part-IIIClinical pathologic conferenceType I dysgammaglobulinemia, systemic lupus erythematosus and lymphomaSerological factors in systemic lupus erythematosus and their pathogenetic significanceTwenty Years of the Lupus Erythematosus CellFREDERIC C. MCDUFFIE, M.D., F.A.C.P.ERYTHROPOIETIC PROTOPORPHYRIA IN TWO SISTERS 1 October 1967Volume 67, Issue 4Page: 780-790KeywordsGlobulinsGraduate medical educationLupus erythematosusMicrobiologyNeutrophils ePublished: 1 December 2008 Issue Published: 1 October 1967 PDF downloadLoading ...